Multimarker RT-PCR Assay for the Detection of Minimal Residual Disease in Sentinel Lymph Nodes of Breast Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Feb 24

PMID 16495929

Citations 22

Authors

A Nissan

D Jager

M Roystacher

D Prus

T Peretz

I Eisenberg

H R Freund

M Scanlan

G Ritter

L J Old

S Mitrani-Rosenbaum

Affiliations

Soon will be listed here.

Abstract

The presence of metastases in lymph nodes is the most powerful prognostic factor in breast cancer patients. Routine histological examination of lymph nodes has limited sensitivity for the detection of breast cancer metastases. The aim of the present study was to develop a multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of minimal residual disease in sentinel nodes of breast cancer patients. RNA was extracted from 30 sentinel lymph nodes (SLN) obtained from 28 patients, three primary breast cancers (positive controls), three lymph nodes from patients with benign diseases, and peripheral blood lymphocytes of 10 healthy volunteers (negative controls). RT-PCR was performed using the following markers; cytokeratin (CK)-19, NY-BR-1 and mammaglobin B. RT-PCR results were compared to enhanced histopathologic examination and immunohistochemistry (IHC). All three positive controls showed strong PCR amplification for all three markers. None of the 13 negative controls was amplified by any of the three markers. Among the 30 SLN analysed, breast cancer metastases were detected in six SLNs by routine histology, in eight by IHC and in 15 by RT-PCR. We conclude that a multimarker RT-PCR assay probing for NY-BR-1, mammaglobin-B, and CK-19 is more sensitive compared to enhanced pathologic examination. This method may prove to be of value in breast cancer staging and prognosis evaluation.

Citing Articles

A clinical diagnostic test on the detection of sentinel lymph node metastasis in breast neoplasms using a 1-step RT-PCR.

Shang J, Zhao M, Deng H, Liu C, Cai L, Liu Y Gland Surg. 2022; 11(10):1628-1638.

PMID: 36353583 PMC: 9638790. DOI: 10.21037/gs-22-485.

Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay.

Meijer S, Klebanov-Akopyn O, Pavlov V, Laks S, Hazzan D, Nissan A Breast Cancer (Dove Med Press). 2021; 13:617-624.

PMID: 34815711 PMC: 8605792. DOI: 10.2147/BCTT.S337075.

The LINC00365/SCGB2A1 (Mammaglobin B) Axis Down-Regulates NF-κB Signaling and Is Associated with the Progression of Gastric Cancer.

Yan X, Zhang J, Zhong X, Yu S, Xu L, Tian R Cancer Manag Res. 2020; 12:621-631.

PMID: 32095083 PMC: 6995300. DOI: 10.2147/CMAR.S223699.

Detection of mammagloblin by RT-PCR as a biomarker for lymph node metastasis in breast cancer patients: A systematic review and meta-analysis.

Monsalve-Lancheros A, Ibanez-Pinilla M, Ramirez-Clavijo S PLoS One. 2019; 14(5):e0216989.

PMID: 31120936 PMC: 6532868. DOI: 10.1371/journal.pone.0216989.

In silico SNP analysis of the breast cancer antigen NY-BR-1.

Kosaloglu Z, Bitzer J, Halama N, Huang Z, Zapatka M, Schneeweiss A BMC Cancer. 2016; 16(1):901.

PMID: 27863482 PMC: 5116164. DOI: 10.1186/s12885-016-2924-7.

References

Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich C . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000; 342(8):525-33. DOI: 10.1056/NEJM200002243420801. View

Cote R, Peterson H, Chaiwun B, Gelber R, Goldhirsch A, Castiglione-Gertsch M . Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999; 354(9182):896-900. DOI: 10.1016/s0140-6736(98)11104-2. View

Aihara T, Fujiwara Y, Ooka M, Sakita I, Tamaki Y, Monden M . Mammaglobin B as a novel marker for detection of breast cancer micrometastases in axillary lymph nodes by reverse transcription-polymerase chain reaction. Breast Cancer Res Treat. 2000; 58(2):137-40. DOI: 10.1023/a:1006335817889. View

Ooka M, Sakita I, Fujiwara Y, Tamaki Y, Yamamoto H, Aihara T . Selection of mRNA markers for detection of lymph node micrometastases in breast cancer patients. Oncol Rep. 2000; 7(3):561-6. DOI: 10.3892/or.7.3.561. View

Li W, Stall A, Shivers S, Lin J, Haddad F, Messina J . Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000; 231(6):795-803. PMC: 1421068. DOI: 10.1097/00000658-200006000-00003. View

Braun S, Cevatli B, Assemi C, Janni W, Kentenich C, Schindlbeck C . Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol. 2001; 19(5):1468-75. DOI: 10.1200/JCO.2001.19.5.1468. View

Jager D, STOCKERT E, Gure A, Scanlan M, Karbach J, Jager E . Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001; 61(5):2055-61. View

Manhani A, Manhani R, Soares H, Bendit I, Lopes F, Nicoletti A . CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat. 2001; 66(3):249-54. DOI: 10.1023/a:1010621901102. View

Euhus D . Cytokeratin staining and other sentinel node controversies. Clin Breast Cancer. 2003; 4 Suppl 1:S49-54. DOI: 10.3816/cbc.2003.s.015. View

10.

Singletary S, Allred C, Ashley P, Bassett L, Berry D, Bland K . Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003; 83(4):803-19. DOI: 10.1016/S0039-6109(03)00034-3. View

11.

Ismail M, Wynendaele W, Aerts J, Paridaens R, Van Mellaert L, Anne J . Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions. Ann Oncol. 2003; 14(8):1241-5. DOI: 10.1093/annonc/mdg341. View

12.

Inokuchi M, Ninomiya I, Tsugawa K, Terada I, Miwa K . Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br J Cancer. 2003; 89(9):1750-6. PMC: 2394408. DOI: 10.1038/sj.bjc.6601248. View

13.

Ouellette R, Richard D, Maicas E . RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes. Am J Clin Pathol. 2004; 121(5):637-43. DOI: 10.1309/MMAC-TXT5-5L8Q-TKC1. View

14.

Chao C . The use of frozen section and immunohistochemistry for sentinel lymph node biopsy in breast cancer. Am Surg. 2004; 70(5):414-9. View

15.

Gillanders W, Mikhitarian K, Hebert R, Mauldin P, Palesch Y, Walters C . Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg. 2004; 239(6):828-37. PMC: 1356291. DOI: 10.1097/01.sla.0000128687.59439.d6. View

16.

Mansel R, Goyal A . European studies on breast lymphatic mapping. Semin Oncol. 2004; 31(3):304-10. DOI: 10.1053/j.seminoncol.2004.03.003. View

17.

Posther K, Wilke L, Giuliano A . Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping. Semin Oncol. 2004; 31(3):426-36. DOI: 10.1053/j.seminoncol.2004.03.019. View

18.

Nemoto T, Vana J, Bedwani R, Baker H, McGregor F, Murphy G . Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980; 45(12):2917-24. DOI: 10.1002/1097-0142(19800615)45:12<2917::aid-cncr2820451203>3.0.co;2-m. View

19.

. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet. 1990; 335(8705):1565-8. View

20.

Schoenfeld A, Luqmani Y, Smith D, OReilly S, Shousha S, Sinnett H . Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res. 1994; 54(11):2986-90. View